What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020)

OBJECTIVE: To examine factors associated with accrual rate in industry sponsored clinical trials supporting US Food and Drug Administration (FDA) cancer drug approvals from 2015 to 2020. DESIGN, SETTING AND PARTICIPANTS: Retrospective cross-sectional study included 194 pivotal trials supporting canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenei, Kristina, Haslam, Alyson, Olivier, Timothée, Miljkovíc, Milos, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558788/
https://www.ncbi.nlm.nih.gov/pubmed/36207035
http://dx.doi.org/10.1136/bmjopen-2022-064458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558788/
https://www.ncbi.nlm.nih.gov/pubmed/36207035
http://dx.doi.org/10.1136/bmjopen-2022-064458

Ejemplares similares